Short-term prognosis of contemporary interventional therapy of ST-elevation myocardial infarction: does gender

Stefan Zimmermann1, Susanne Ruthrof, Kathrin Nowak

  • 1Medizinische Klinik 2 (Kardiologie/Angiologie), Universitätsklinikum Erlangen, 91054 Erlangen, Germany. stefan.zimmermann@uk-erlangen.de

Insights

Women with ST-elevation myocardial infarction (STEMI) experienced longer pre-hospital delays but received similar percutaneous coronary intervention (PCI) treatment and success rates as men. Despite older age and comorbidities, 30-day mortality was not significantly higher for women.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Gender-Specific Medicine

Background:

  • Historically, women with ST-elevation myocardial infarction (STEMI) faced higher mortality risks, even post-percutaneous coronary intervention (PCI).
  • Contemporary data on gender differences in STEMI treatment and outcomes remain crucial for clinical practice.

Purpose of the Study:

  • To investigate gender-specific differences in the treatment and outcomes of acute ST-elevation myocardial infarction (STEMI) in a real-world setting.
  • To analyze contemporary trends in percutaneous coronary intervention (PCI) for STEMI, focusing on patient characteristics, procedural success, and short-term mortality.

Main Methods:

  • Retrospective analysis of 566 consecutive STEMI patients undergoing acute coronary angiography with intent for PCI (June 1999-June 2006).
  • Examination of gender-specific differences in patient demographics, referral patterns, symptom onset to admission delays, angiographic findings, PCI procedural details, and 30-day adverse events.

Main Results:

  • Women were older, had higher comorbidity, and longer pre-hospital delays (185 min vs. 135 min) but received PCI with similar frequency (88.8% vs. 92.4%) and success rates (83.2% vs. 85.3%) as men.
  • Thirty-day mortality was not significantly different between genders (8.7% vs. 7.2%).
  • Women experienced more bleeding events requiring transfusion (16.8% vs. 5.9%), but female gender was not an independent predictor of 30-day mortality.

Conclusions:

  • Women with STEMI receive contemporary PCI therapy with comparable frequency and angiographic success to men.
  • Despite older age and higher comorbidity, women do not exhibit significantly higher 30-day mortality after PCI for STEMI.
  • Longer pre-hospital delays in women highlight the need to increase awareness of coronary artery disease risks in this population.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...